CCR2 and focal segmental glomerulosclerosis: The inhibition of CCR2 has been found to improve outcomes in animal models of FSGS (17), and several trials are currently underway to evaluate the impact of CCR2 inhibitors on FSGS patients (NCT03649152, NCT03536754, NCT03703908) (49).